In Alzheimer's disease, researchers have identified genetic variants and other risk factors related to diet, lifestyle, the environment, but...
Vous n'êtes pas connecté
In Alzheimer's disease, researchers have identified genetic variants and other risk factors related to diet, lifestyle, the environment, but metal levels in the brain also contribute to the condition.1 Imbalanced levels of iron, copper, and zinc can promote features of Alzheimer’s pathology such as amyloid-β (Aβ) aggregation, tau phosphorylation, and oxidative stress.2 However, there are other metals that contribute to brain function, and how these are affected or disrupted in Alzheimer’s disease is still largely unexplored. To tackle this metal mystery further, researchers from Harvard Medical School and Rush University Medical Center teamed up. When they...
In Alzheimer's disease, researchers have identified genetic variants and other risk factors related to diet, lifestyle, the environment, but...
Higher brain copper levels are linked to slower cognitive decline and lower Alzheimer's pathology, shows a 20-year study.
Higher brain copper levels are linked to slower cognitive decline and lower Alzheimer's pathology, shows a 20-year study.
A new study reveals that a combination of nicotinamide and epigallocatechin gallate, found in green tea, can rejuvenate aging brain cells. The...
A new study reveals that a combination of nicotinamide and epigallocatechin gallate, found in green tea, can rejuvenate aging brain cells. The...
Researchers from the University of California, San Francisco (UCSF) have uncovered new insights into how Alzheimer’s disease spreads in the brain...
Researchers from the University of California, San Francisco (UCSF) have uncovered new insights into how Alzheimer’s disease spreads in the brain...
Researchers have uncovered a new factor that could contribute to Alzheimer’s disease...
Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows disease progression...
Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows disease progression...